Brief: Cullinan Oncology And Taiho Pharmaceutical Complete Agreement For Strategic Collaboration To Jointly Develop And Commercialize Cln-081/Tas6417

Cullinan Therapeutics

23/06/2022 13:25

Cullinan Oncology Inc  CGEM.O :
    * CULLINAN ONCOLOGY AND TAIHO PHARMACEUTICAL COMPLETE
AGREEMENT
FOR STRATEGIC COLLABORATION TO JOINTLY DEVELOP AND COMMERCIALIZE
CLN-081/TAS6417
    * CULLINAN ONCOLOGY - GETS UPFRONT CASH PAYMENT OF $275
MILLION,
WITH POTENTIAL TO GET UP TO AN ADDITIONAL $130 MILLION IN
REGULATORY-BASED MILESTONE PAYMENTS
    * CULLINAN ONCOLOGY INC - TAIHO OBTAINS EXCLUSIVE GLOBAL
RIGHTS TO
CLN-081/TAS6417 OUTSIDE U.S.
    * CULLINAN ONCOLOGY INC - TAIHO AND CULLINAN ONCOLOGY TO
JOINTLY
DEVELOP AND CO-COMMERCIALIZE CLN-081/TAS6417 IN U.S.
    * CULLINAN ONCOLOGY INC - CULLINAN ONCOLOGY AND TAIHO WILL
EQUALLY
SHARE FUTURE PROFITS IN U.S.
    * CULLINAN ONCOLOGY INC - RETAINS OPTION TO CO-COMMERCIALIZE
CLN-081/TAS6417 IN UNITED STATES TOGETHER WITH TAIHO THROUGH ITS
U.S. SUBSIDIARY

Source text for Eikon:  ID:nGNX9Lhz5L 
Further company coverage:  CGEM.O